The abstract is read at the publisher; the summary is JClub's.
Ifabotuzumab-PBD ADC is the most efficacious EphA3-targeted antibody-drug conjugate, showing highest in-vitro potency and the strongest tumour growth reduction and survival benefit in mice.
- Why it matters: EphA3 is over-expressed in tumours, especially in the tumour microenvironment and immunosuppressive cancer-associated fibroblasts, while normal tissues show little expression, creating a therapeutic targeting gap.
- What they did: The study built Ifabotuzumab ADCs with MMAE, DXd, or PBD using cleavable linkers and AJICAP site-specific conjugation, then tested EphA3 binding, dose-dependent killing, and efficacy in tumour xenografts and syngeneic stromal-EphA3 models.
- The result: Ifabotuzumab-PBD alone killed EphA3-expressing cancer-associated fibroblasts, inhibited stromal-only EphA3 tumours in immunocompetent mice, and combined with anti-PD1 increased CD8+ T cells and improved tumour inhibition versus anti-PD1 alone.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.